A Phase 2 interventional study of NNC6019-0001 in Transthyretin Amyloid Cardiomyopathy (ATTR CM), sponsored by Novo Nordisk A/S. Active, not recruiting at 38 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long term and if it can reduce symptoms of a heart disease due to TTR amyloidosis, such as heart failure. It is an extension to a study called "A research study to look at how a new medicine called NNC6019-0001 works and how safe it is for people who have a heart disease due to TTR amyloidosis". Only participants who have completed that study will be invited for this new study. Participants will get NNC6019-0001, regardless of whether they got placebo or NNC6019-0001 in the first study. The study will last for approximately 6 years or until NNC6019-0001 is commercially or otherwise available to the participant, whichever comes first.
Novo Nordisk A/S is the lead sponsor of 1,410 studies on the registry; 107 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will receive NNC6019-0001 intravenously every 4 weeks added to the standard of care up to 300 weeks.
Drug: NNC6019-0001
Intravenous NNC6019-0001 every 4 weeks added to the standard of care up to 300 weeks.
Number of Treatment Emergent Adverse Events (TEAEs)
Measured as events.
Time frame: From baseline (week 0) to up to 6 years
Change in 6-Minute Walk Test (6MWT)
Measured in meters.
Time frame: From baseline (week 0) to visit 28 (week 104)
Change in N-terminal-pro brain natriuretic peptide (NT-proBNP)
Measured in percentage.
Time frame: From baseline (week 0) to visit 28 (week 104)
Change in Myocardial Extracellular Volume (ECV)
Measured in percentage-points.
Time frame: From baseline (week 0) to visit 28 (week 104)
Change in Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS)
The KCCQ is a disease-specific health status instrument composed of 23 items that quantify the domains of physical limitation, symptoms, self-efficacy, social limitation, and health-related quality of life limitation from heart failure. The overall summary score and all domains have been independently demonstrated to be valid, reliable, and responsive to clinical change. CSS scores range from 0 to 100 and lower scores represent more severe symptoms and/or limitations and scores of 100 indicate no symptoms, no limitations, and excellent quality of life. Measured in score on a scale.
Time frame: From baseline (week 0) to visit 28 (week 104)
Change in Troponin I
Measured in nanogram per milliliter (ng/mL).
Time frame: From baseline (week 0) to visit 28 (week 104)
Change in Global Longitudinal Strain (GLS) on Echocardiography
Measured in percentage-points.
Time frame: From baseline (week 0) to visit 28 (week 104)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
No publications or documents are linked to this record.
Started Feb 2024 (actual). Primary completion is estimated for Feb 2028, 48 months after the start.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2028 → Feb 2030, on Sep 30, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: NNC6019-0001